Tamer I. Khayal Sells 63,260 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the transaction, the insider now directly owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $127.99 on Friday. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $129.66. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock has a market capitalization of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The company’s 50 day simple moving average is $85.54 and its two-hundred day simple moving average is $77.08.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. During the same period in the prior year, the company posted ($0.08) EPS. The business’s revenue for the quarter was up 132.9% compared to the same quarter last year. Analysts predict that TransMedics Group, Inc. will post 0.54 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Harbour Capital Advisors LLC boosted its stake in shares of TransMedics Group by 1.7% during the 4th quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares in the last quarter. RiverPark Advisors LLC lifted its position in TransMedics Group by 19.5% during the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after acquiring an additional 215 shares during the period. First Horizon Advisors Inc. lifted its position in TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after acquiring an additional 222 shares during the period. Park Avenue Securities LLC lifted its position in TransMedics Group by 3.4% during the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock valued at $841,000 after acquiring an additional 372 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in TransMedics Group during the 1st quarter valued at about $30,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on TMDX. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research note on Wednesday. TD Cowen upped their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Piper Sandler restated an “overweight” rating and set a $120.00 price target (up from $95.00) on shares of TransMedics Group in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.